Trial of Docetaxel-Samarium in Patients With Hormone-Refractory Advanced Prostate Cancer

Inclusion Criteria

• •Patients older than 18 years and less than 80 years
• •Histologically-proven adenocarcinoma of the prostate
• •Evidence of bone metastases and progressive, hormone-refractory, disease
• •No previous chemotherapy
• •No previous radiotherapy, except radiotherapy directed to the prostate and/or to a single bony lesion
• •No previous carcinoma, except basal-cell carcinoma of the skin
• •Adequate renal function: measured or calculated creatinine clearance \> 60 ml/min
• •Absolute granulocyte count ≥ 1,500/mm3, platelets ≥ 100,000 mm3, bilirubin ≤ 1.5 fold the upper normal value
• •Signed informed consent.